Share
ISSN: 0214-9168
Clínica e Investigación en Arteriosclerosis ha recibido Factor de Impacto (JCR) por primera vez en 2023.
Guía para autores
-
Envío de manuscritos
"Notas metodológicas": una nueva e importante sección en Clínica e Investigación en Arteriosclerosis
Indexed in:
Web of Science, Index Medicus/MEDLINE, Scopus, IBECS, IME, MEDES
See moreFollow us:
Subscribe:
Impact factor
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© Clarivate Analytics, Journal Citation Reports 2022
Impact factor 2022
1.6
Citescore 2022
3
SJR
SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.
See moreSJR 2022
0.36
SNIP
SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.
See moreSNIP 2022
0.605
View more metrics
Hide
Journal Information
Issue
Vol. 31. Issue S1.Estándares SEA 2019 para el control global del riesgo cardiovascularStandards for global cardiovascular risk management arteriosclerosis
Pages 1-44 (July 2019)
Artículo especial
Estándares SEA 2019 para el control global del riesgo cardiovascular
José María Mostaza, Xavier Pintó, Pedro Armario, Luis Masana, Juan F. Ascaso, Pedro Valdivielso
Clin Invest Arterioscl. 2019;31 Supl 1:1-43
Open access
Open Article
Publish in
Clínica e Investigación en Arteriosclerosis
Highlighted articles
Special content about COVID-19
- Thrombotic risk assessed by PAI-1 in patients with COVID-19: The influence of hyperglycemia and diabetes mellitus
- Absence of the influence of the APOE gene on the incidence of type 2 diabetes mellitus in a cohort of workers: Effect of diet and shift work
- Dietary modulation of advanced glycation end products metabolism on carotid intima-media thickness in type 2 diabetes patients: From the CORDIOPREV study
- Impacto de la pandemia por COVID-19 en el control lipídico de pacientes que inician inhibidores de la PCSK9